Potent Personalized Venetoclax Partners for Acute Myeloid Leukemia Identified by Ex Vivo Drug Screening.

Overview of attention for article published in Blood Cancer Discovery, October 2023

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (56th percentile)
Average Attention Score compared to outputs of the same age and source

So far, Altmetric has seen 6 X posts from 3 X users, with an upper bound of 3,040 followers.

In Focus from the latest issue— Potent Personalized #Venetoclax Partners for #AcuteMyeloidLeukemia Identified by Ex Vivo Drug Screening, by Pamela S. Becker. https://t.co/VU30ONFEcY @cityofhope #AMLsm #precisionmedicine #TheSFPM https://t.co/KB4B5yB2mH

In Focus from the November issue— Potent Personalized #Venetoclax Partners for #AcuteMyeloidLeukemia Identified by Ex Vivo Drug Screening, by Pamela S. Becker. https://t.co/Ti6lyeI8EF @cityofhope #AMLsm #precisionmedicine #TheSFPM https://t.co/Kraa5hHKMJ

RT @BCD_AACR: Potent Personalized #Venetoclax Partners for #AcuteMyeloidLeukemia Identified by Ex Vivo Drug Screening, by Pamela S. Becker.…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 2 additional X posts.